JP2013510905A - サイトカイン及びｎｆ−ｋｂに影響を与える組成物及び方法 - Google Patents
サイトカイン及びｎｆ−ｋｂに影響を与える組成物及び方法 Download PDFInfo
- Publication number
- JP2013510905A JP2013510905A JP2012539974A JP2012539974A JP2013510905A JP 2013510905 A JP2013510905 A JP 2013510905A JP 2012539974 A JP2012539974 A JP 2012539974A JP 2012539974 A JP2012539974 A JP 2012539974A JP 2013510905 A JP2013510905 A JP 2013510905A
- Authority
- JP
- Japan
- Prior art keywords
- plant filtrate
- plant
- cytokines
- affecting
- various
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 73
- 102000004127 Cytokines Human genes 0.000 title claims abstract description 61
- 108090000695 Cytokines Proteins 0.000 title claims abstract description 61
- 239000000203 mixture Substances 0.000 title abstract description 64
- 239000000706 filtrate Substances 0.000 claims abstract description 105
- 108010057466 NF-kappa B Proteins 0.000 claims abstract description 56
- 102000003814 Interleukin-10 Human genes 0.000 claims abstract description 33
- 108090000174 Interleukin-10 Proteins 0.000 claims abstract description 33
- 206010061218 Inflammation Diseases 0.000 claims abstract description 28
- 230000004054 inflammatory process Effects 0.000 claims abstract description 28
- 108010002350 Interleukin-2 Proteins 0.000 claims abstract description 27
- 102000000588 Interleukin-2 Human genes 0.000 claims abstract description 27
- 102000015696 Interleukins Human genes 0.000 claims abstract description 9
- 108010063738 Interleukins Proteins 0.000 claims abstract description 9
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 8
- 201000011510 cancer Diseases 0.000 claims abstract description 6
- 230000000694 effects Effects 0.000 claims description 36
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 34
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 34
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims description 29
- 108010074328 Interferon-gamma Proteins 0.000 claims description 20
- 102100037850 Interferon gamma Human genes 0.000 claims description 18
- 102000013691 Interleukin-17 Human genes 0.000 claims description 18
- 108050003558 Interleukin-17 Proteins 0.000 claims description 18
- 230000002757 inflammatory effect Effects 0.000 claims description 14
- 230000004568 DNA-binding Effects 0.000 claims description 13
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 13
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 10
- 241000700605 Viruses Species 0.000 claims description 7
- 230000003247 decreasing effect Effects 0.000 claims description 6
- 244000005700 microbiome Species 0.000 claims description 5
- 230000000770 proinflammatory effect Effects 0.000 claims description 5
- 230000034190 positive regulation of NF-kappaB transcription factor activity Effects 0.000 claims description 4
- 210000000987 immune system Anatomy 0.000 claims description 3
- 230000004913 activation Effects 0.000 claims description 2
- 230000001413 cellular effect Effects 0.000 claims description 2
- 230000002222 downregulating effect Effects 0.000 claims description 2
- 230000028993 immune response Effects 0.000 claims description 2
- 102100023050 Nuclear factor NF-kappa-B p105 subunit Human genes 0.000 claims 7
- 238000012258 culturing Methods 0.000 claims 3
- 230000014509 gene expression Effects 0.000 claims 2
- 101000979342 Homo sapiens Nuclear factor NF-kappa-B p105 subunit Proteins 0.000 claims 1
- 230000005856 abnormality Effects 0.000 claims 1
- 230000005745 host immune response Effects 0.000 claims 1
- 230000000813 microbial effect Effects 0.000 claims 1
- 102000003945 NF-kappa B Human genes 0.000 abstract description 50
- 229940047122 interleukins Drugs 0.000 abstract description 8
- 102000040945 Transcription factor Human genes 0.000 abstract description 3
- 108091023040 Transcription factor Proteins 0.000 abstract description 3
- 208000035473 Communicable disease Diseases 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 238000010790 dilution Methods 0.000 description 56
- 239000012895 dilution Substances 0.000 description 56
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 50
- 238000004519 manufacturing process Methods 0.000 description 31
- 210000004027 cell Anatomy 0.000 description 30
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 30
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 26
- 239000011347 resin Substances 0.000 description 25
- 229920005989 resin Polymers 0.000 description 25
- 230000028327 secretion Effects 0.000 description 21
- 230000008569 process Effects 0.000 description 18
- 238000011282 treatment Methods 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 18
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 13
- 239000002609 medium Substances 0.000 description 13
- 108090000623 proteins and genes Proteins 0.000 description 13
- 239000011780 sodium chloride Substances 0.000 description 13
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 10
- 230000001603 reducing effect Effects 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- GUBGYTABKSRVRQ-WFVLMXAXSA-N DEAE-cellulose Chemical compound OC1C(O)C(O)C(CO)O[C@H]1O[C@@H]1C(CO)OC(O)C(O)C1O GUBGYTABKSRVRQ-WFVLMXAXSA-N 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 9
- 230000001965 increasing effect Effects 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 235000015097 nutrients Nutrition 0.000 description 9
- 239000008367 deionised water Substances 0.000 description 8
- 229910021641 deionized water Inorganic materials 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 239000011521 glass Substances 0.000 description 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 235000016709 nutrition Nutrition 0.000 description 6
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 5
- 239000002028 Biomass Substances 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 239000003957 anion exchange resin Substances 0.000 description 5
- 238000005341 cation exchange Methods 0.000 description 5
- 238000005194 fractionation Methods 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 229910021642 ultra pure water Inorganic materials 0.000 description 5
- 239000012498 ultrapure water Substances 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- 239000011324 bead Substances 0.000 description 4
- 230000027455 binding Effects 0.000 description 4
- 230000004073 interleukin-2 production Effects 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 241000195493 Cryptophyta Species 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 241000233866 Fungi Species 0.000 description 3
- 102000011931 Nucleoproteins Human genes 0.000 description 3
- 108010061100 Nucleoproteins Proteins 0.000 description 3
- 239000012980 RPMI-1640 medium Substances 0.000 description 3
- 238000005349 anion exchange Methods 0.000 description 3
- 239000003729 cation exchange resin Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000003501 co-culture Methods 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 230000016784 immunoglobulin production Effects 0.000 description 3
- PGHMRUGBZOYCAA-ADZNBVRBSA-N ionomycin Chemical compound O1[C@H](C[C@H](O)[C@H](C)[C@H](O)[C@H](C)/C=C/C[C@@H](C)C[C@@H](C)C(/O)=C/C(=O)[C@@H](C)C[C@@H](C)C[C@@H](CCC(O)=O)C)CC[C@@]1(C)[C@@H]1O[C@](C)([C@@H](C)O)CC1 PGHMRUGBZOYCAA-ADZNBVRBSA-N 0.000 description 3
- PGHMRUGBZOYCAA-UHFFFAOYSA-N ionomycin Natural products O1C(CC(O)C(C)C(O)C(C)C=CCC(C)CC(C)C(O)=CC(=O)C(C)CC(C)CC(CCC(O)=O)C)CCC1(C)C1OC(C)(C(C)O)CC1 PGHMRUGBZOYCAA-UHFFFAOYSA-N 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000037230 mobility Effects 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 230000001151 other effect Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000013341 scale-up Methods 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical group [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 102000008070 Interferon-gamma Human genes 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 239000000356 contaminant Substances 0.000 description 2
- 238000012136 culture method Methods 0.000 description 2
- 230000016396 cytokine production Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000013505 freshwater Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 229940045109 genistein Drugs 0.000 description 2
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 description 2
- 235000006539 genistein Nutrition 0.000 description 2
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 description 2
- 230000005484 gravity Effects 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 229960003130 interferon gamma Drugs 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 239000003456 ion exchange resin Substances 0.000 description 2
- 229920003303 ion-exchange polymer Polymers 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 210000005087 mononuclear cell Anatomy 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 230000002572 peristaltic effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- NEWKHUASLBMWRE-UHFFFAOYSA-N 2-methyl-6-(phenylethynyl)pyridine Chemical compound CC1=CC=CC(C#CC=2C=CC=CC=2)=N1 NEWKHUASLBMWRE-UHFFFAOYSA-N 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 108020003215 DNA Probes Proteins 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- -1 G2535 alone Chemical compound 0.000 description 1
- 101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 description 1
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 1
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 1
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 1
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 210000004241 Th2 cell Anatomy 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000012627 chemopreventive agent Substances 0.000 description 1
- 229940124443 chemopreventive agent Drugs 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 238000010908 decantation Methods 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000002828 effect on organs or tissue Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 230000003480 fibrinolytic effect Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000011491 glass wool Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 230000000887 hydrating effect Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000003960 inflammatory cascade Effects 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000005651 interleukin-17A production Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000011785 micronutrient Substances 0.000 description 1
- 235000013369 micronutrients Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000009149 molecular binding Effects 0.000 description 1
- 230000037125 natural defense Effects 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000005464 sample preparation method Methods 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 238000009331 sowing Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 125000001273 sulfonato group Chemical group [O-]S(*)(=O)=O 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 230000003956 synaptic plasticity Effects 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000006433 tumor necrosis factor production Effects 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- 239000012610 weak anion exchange resin Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/02—Algae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Alternative & Traditional Medicine (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26163909P | 2009-11-16 | 2009-11-16 | |
| US61/261,639 | 2009-11-16 | ||
| PCT/US2010/056862 WO2011060427A2 (en) | 2009-11-16 | 2010-11-16 | Composition and methods for affecting cytokines and nf-kb |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013510905A true JP2013510905A (ja) | 2013-03-28 |
| JP2013510905A5 JP2013510905A5 (enExample) | 2014-01-16 |
Family
ID=43992472
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012539974A Pending JP2013510905A (ja) | 2009-11-16 | 2010-11-16 | サイトカイン及びｎｆ−ｋｂに影響を与える組成物及び方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20110117122A1 (enExample) |
| EP (1) | EP2501390A4 (enExample) |
| JP (1) | JP2013510905A (enExample) |
| BR (1) | BR112012011678A2 (enExample) |
| CA (1) | CA2780144A1 (enExample) |
| WO (1) | WO2011060427A2 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10166270B2 (en) | 2004-04-23 | 2019-01-01 | Zivo Bioscience, Inc. | Composition and method for affecting cytokines and NF-κB |
| CA2827401A1 (en) | 2010-02-22 | 2011-08-25 | Health Enhancement Products, Inc. | Agents and mechanisms for treating hypercholesterolemia |
| WO2014201372A1 (en) | 2013-06-13 | 2014-12-18 | Health Enhancement Products, Inc. | Compounds and methods for affecting cytokines |
| ES2972377T3 (es) | 2015-02-16 | 2024-06-12 | Zivo Bioscience Inc | Composiciones antinflamatorias e inmunomoduladoras que comprenden Klebsormidium y usos de las mismas |
| US11806375B2 (en) | 2016-02-16 | 2023-11-07 | Zivo Bioscience, Inc. | Nutritional support for animals via administration of an algal derived supplement |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005112987A2 (en) * | 2004-04-23 | 2005-12-01 | Health Enhancement Products, Inc. | Method of preparation and use of fibrinolytic enzymes in the treatment of disease |
| JP2009518312A (ja) * | 2005-12-02 | 2009-05-07 | ヘルス エンハンスメント プロダクツ インク | 疾患を治療するための植物浸出物の組成物および使用 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9479A (en) * | 1852-12-21 | Improvement in rakes to grain-harvesters | ||
| US10480A (en) * | 1854-01-31 | Improvement in electro-magnettc engines | ||
| US15587A (en) * | 1856-08-19 | Aepabattts for boeing artesian wells | ||
| JPS6219528A (ja) * | 1985-07-16 | 1987-01-28 | Kurorera Kogyo Kk | 制癌剤 |
| US6461607B1 (en) * | 1998-08-24 | 2002-10-08 | Ganeden Biotech, Inc. | Probiotic, lactic acid-producing bacteria and uses thereof |
| US6673908B1 (en) * | 1999-02-22 | 2004-01-06 | Nuvelo, Inc. | Tumor necrosis factor receptor 2 |
| WO2001013956A2 (en) * | 1999-08-26 | 2001-03-01 | Ganeden Biotech, Inc. | Use of emu oil a carrier for antifungal, antibacterial, and antiviral medications |
| AU7551100A (en) * | 1999-09-27 | 2001-04-30 | Algal Ltd. | Vegetarian foodstuff |
| EP1307213B1 (en) * | 2000-08-10 | 2004-04-28 | Ocean Nutrition Canada Ltd. | Chlorella preparations exhibiting immunomodulating properties |
| US20020119164A1 (en) * | 2000-08-18 | 2002-08-29 | Shoji Uchiyama | Use of agaricus blazei murill to prevent or treat skin and other disorders |
| US7125846B2 (en) * | 2001-11-09 | 2006-10-24 | Novo Nordisk Healthcare A/G | Pharmaceutical composition comprising factor VII polypeptides and factor V polypeptides |
| EP1629090B1 (en) * | 2002-11-06 | 2014-03-05 | iBio, Inc. | Expression of foreign sequences in plants using trans-activation system |
| US20130251698A1 (en) * | 2010-10-04 | 2013-09-26 | Health Enhancement Products, Inc. | Composition and method for affecting cytokines and nf-kb |
| US7807622B2 (en) | 2004-04-23 | 2010-10-05 | Health Enhancement Products, Inc. | Composition and use of phyto-percolate for treatment of disease |
| CA2625818A1 (en) * | 2005-04-20 | 2006-10-26 | Health Enhancement Products, Inc. | Composition and use of phyto-percolate for treatment of disease |
-
2010
- 2010-11-16 US US12/947,684 patent/US20110117122A1/en not_active Abandoned
- 2010-11-16 EP EP10830908.9A patent/EP2501390A4/en not_active Ceased
- 2010-11-16 WO PCT/US2010/056862 patent/WO2011060427A2/en not_active Ceased
- 2010-11-16 JP JP2012539974A patent/JP2013510905A/ja active Pending
- 2010-11-16 BR BR112012011678A patent/BR112012011678A2/pt not_active Application Discontinuation
- 2010-11-16 CA CA2780144A patent/CA2780144A1/en not_active Abandoned
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005112987A2 (en) * | 2004-04-23 | 2005-12-01 | Health Enhancement Products, Inc. | Method of preparation and use of fibrinolytic enzymes in the treatment of disease |
| JP2009518312A (ja) * | 2005-12-02 | 2009-05-07 | ヘルス エンハンスメント プロダクツ インク | 疾患を治療するための植物浸出物の組成物および使用 |
Non-Patent Citations (4)
| Title |
|---|
| JPN6014046735; Ｊｕｌｉｕｓ Ｏｂｅｎ， ｅｔ ａｌ．: 'Ｔｈｅ ｅｆｆｅｃｔｓ ｏｆ ＰｒｏＡｌｇａＺｙｍｅ ｎｏｖｅｌ ａｌｇａｅ ｉｎｆｕｓｉｏｎ ｏｎ ｍｅｔａｂｏｌｉｃ ｓｙｎｄｒｏｍｅ ａｎｄ ｍａｒｋｅｒｓ ｏｆ ｃａｒｄｉｏｖａｓｃｕｌａｒ' Ｌｉｐｉｄｓ Ｈｅａｌｔｈ Ｄｉｓ ６（２０）, 2007, １-９ * |
| JPN6014046736; 'Ｗｅｓｔｅｒｎ Ｇｌｏｒｙ Ｈｏｌｅ Ｉｎｃ． Ｅｎｔｅｒｓ Ｄｅｆｉｎｉｔｉｖｅ Ａｇｒｅｅｍｅｎｔ ｗｉｔｈ Ｈｅａｌｔｈ Ｅｎｈａｎｃｅｍｅｎｔ Ｐｒｏｄｕｃｔｓ Ｉｎｃ．' ｏｎｌｉｎｅ , 20031030 * |
| JPN6014046738; 藤田浩: '炎症反応の機構とその制御のための新戦略 炎症のシグナル伝達の制御および遺伝子操作 ＮＦ-kappaＢ' 医学のあゆみ １９０（１０）, 1999, ９１３-６ * |
| JPN6014046740; 岡田英理子ら: '炎症性腸疾患とサイトカイン' 医学のあゆみ 別冊（１０月）, 2004, ２６５-８ * |
Also Published As
| Publication number | Publication date |
|---|---|
| EP2501390A4 (en) | 2014-07-02 |
| US20110117122A1 (en) | 2011-05-19 |
| EP2501390A2 (en) | 2012-09-26 |
| CA2780144A1 (en) | 2011-05-19 |
| WO2011060427A9 (en) | 2011-09-15 |
| BR112012011678A2 (pt) | 2018-04-17 |
| WO2011060427A2 (en) | 2011-05-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10765732B2 (en) | Compounds and methods for affecting cytokines | |
| US20230183642A1 (en) | Method of producing plant-derived exosomes | |
| RU2743715C1 (ru) | Способ получения целастрола и пентациклических тритерпеновых производных | |
| US20110117122A1 (en) | COMPOSITION AND METHOD FOR AFFECTING CYTOKINES AND NF-kB | |
| Baek et al. | Parabiotic immunomodulatory activity of yeast cell wall polysaccharides from Saccharomyces cerevisiae and S. boulardii | |
| US20130251698A1 (en) | Composition and method for affecting cytokines and nf-kb | |
| Zheng et al. | Novel organic selenium source hydroxy-selenomethionine counteracts the blood-milk barrier disruption and inflammatory response of mice under heat stress | |
| US10166270B2 (en) | Composition and method for affecting cytokines and NF-κB | |
| EP3148574A1 (en) | Purified compositions of ivig and kh proteins for modulating lymphocytes and treating hepatitis b virus | |
| RU2146935C1 (ru) | Сухой иммунопробиотический препарат для птицеводства | |
| Yang et al. | Nervonic acid mitigates IMQ-triggered psoriasis in mice via inhibiting Th17/γδT17 cell invasion and modulating the gut microbiota | |
| CN118370247A (zh) | 一种提高香港巨牡蛎在高盐条件下存活率的方法 | |
| JPH08512326A (ja) | 免疫調節、補強治療のための製剤組成物 | |
| RU2846087C1 (ru) | Способ получения происходящих из растений экзосом | |
| Meijer et al. | Membrane and transformation characteristics of lymphocytes isolated from the synovial membrane and paired peripheral blood of patients with rheumatoid arthritis | |
| CN116270379B (zh) | 一种能够使皮肤美白的芦根提取物及其制备方法和应用 | |
| JP6997488B1 (ja) | 高脂肪食に起因する肥満関連低度炎症と腸内細菌群紊乱の改善におけるナノ銀製剤の使用 | |
| Basir et al. | Antibacterial activity test of Moringa leaf ethanol extract ointment of Moringa oleifera Lamk. on Staphylococcus aureus bacteria | |
| Harfi et al. | Long Term Remission of Hyper IgE Syndrome after Treatment with Cyclosporine-A: Clinic and Immunological Correlations | |
| Yu-jie et al. | Enhanced Responsive Formation of Extracellular Traps in Macrophages Previously Exposed to Porphyromonas gingivalis | |
| RU2471873C2 (ru) | Способ препаративного выделения основных белков из надмолекулярных структур растущей популяции escherichia coli | |
| Jilo | A study of antimicrobial activities of aqueous and ethanolic extract of bee pollen against | |
| Fathima et al. | Impact of algal β-glucan on stress, humoral immunity, plasma biomarkers, and carcass traits of broiler chickens reared during hot season | |
| Hoch-Ligeti et al. | Catecholamine production in tissue cultures of human adrenal medullary tumors and of adrenal medulla. | |
| RU2629592C1 (ru) | Средство для лечения хламидиоза |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20131114 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20131114 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20131128 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20141111 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20150202 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20150707 |